Table 2. Cox regression examination of clinical results in IBC individuals depending on different clinicopathological features.
| Characteristics | HR for overall survival (95% CI) | HR for disease-specific survival (95% CI) | HR for progression-free survival (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||
| T stage (T3&T4 vs. T1&T2) | 1.673** | 2.470* | 2.037** | 0.847 | 2.117*** | 1.026 | ||
| N stage (N1&N2&N3 vs. N0) | 2.145 *** | 1.004 | 3.584*** | 1.877 | 2.250*** | 1.363 | ||
| M stage (M1 vs. M0) | 4.327*** | 1.965 | 7.697*** | 5.114*** | 8.288*** | 4.167*** | ||
| Pathologic stage (Stage III&IV vs. I&II) | 2.519*** | 2.259 | 3.870*** | 2.559* | 2.962*** | 2.030* | ||
| Age (>60 vs. ≤60) | 2.036*** | 2.645** | 1.418 | – | 1.232 | – | ||
| ER status (positive vs. negative) | 0.704 | 0.369* | 0.523** | 0.420* | 0.599** | 0.784 | ||
| PR status (positive vs. negative) | 0.762 | – | 0.529** | 0.881 | 0.567*** | 0.638 | ||
| PAM50 (LumA&LumB&Basal vs. Her2) | 0.509** | 0.830 | 0.447* | 0.842 | 0.529* | 0.806 | ||
| Menopause status (Pre&Peri vs. Post) | 0.416*** | 0.332* | 0.628 | – | 0.889 | – | ||
| Radiation_therapy (yes vs. no) | 0.558** | 0.470* | 0.755 | – | 0.885 | – | ||
| CIAPIN1 (high vs. low) | 1.287 | – | 1.772 * | 1.513 | 1.482* | 1.192 | ||
*, P<0.05, **, P<0.01, ***, P<0.001. IBC, invasive breast cancer; HR, hazard ratio; CI, confidential interval; T, tumor; N, lymph node; M, metastasis; ER, estrogen receptor; PR, progesterone receptor; PAM50, prediction analysis of microarray 50; CIAPIN1, Cytokine-induced apoptosis inhibitor 1.